Abstract
Oncolytic vaccinia viruses have made some impressive advances over the last 5 years, with a range of different backbones displaying significant antitumor responses in preclinical models, and some exciting clinical results being reported against liver cancers. Because the virus is capable of rapid spread within the tumor, has evolved to spread relatively undetected within the blood stream, does not integrate into the host cell chromosome, and can infect almost any cell type, it is well-suited to the requirements for a successful oncolytic. In addition, the extensive clinical use of this virus means that contraindications to its use are known, and approved and experimental antivirals are available. Furthermore, because the virus has a large array of virulence genes whose deletion may target different properties of the cancer cell, and a large cloning capacity allowing for insertion of multiple transgenes, the possibilities for further development of novel and next-generation oncolytic vectors are multitude.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Smith GL, Symons JA, Khanna A, Vanderplasschen A, Alcami A. 1997 Vaccinia virus immune evasion. Immunol Rev;159:137–54.
Buller RM, Palumbo GJ. 1991 Poxvirus pathogenesis. Microbiol Rev;55:80–122.
Thorne SH, Hwang TH, Kirn DH. 2005 Vaccinia virus and oncolytic virotherapy of cancer. Curr Opin Mol Ther;7:359–65.
Thorne SH, Kirn DH. 2004 Future directions for the field of oncolytic virotherapy: a perspective on the use of vaccinia virus. Expert Opin Biol Ther;4:1307–21.
Chakrabarti S, Sisler JR, Moss B. 1997 Compact, synthetic, vaccinia virus early/late promoter for protein expression. Biotechniques;23:1094–7.
Coupar BE, Oke PG, Andrew ME. 2000 Insertion sites for recombinant vaccinia virus construction: effects on expression of a foreign protein. J Gen Virol;81:431–9.
Zhao H, Doyle TC, Coquoz O, Kalish F, Rice BW, Contag CH. 2005 Emission spectra of bioluminescent reporters and interaction with mammalian tissue determine the sensitivity of detection in vivo. J Biomed Opt;10:41210.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Thorne, S.H. (2012). Next-Generation Oncolytic Vaccinia Vectors. In: Kirn, D., Liu, TC., Thorne, S. (eds) Oncolytic Viruses. Methods in Molecular Biology, vol 797. Humana, Totowa, NJ. https://doi.org/10.1007/978-1-61779-340-0_14
Download citation
DOI: https://doi.org/10.1007/978-1-61779-340-0_14
Published:
Publisher Name: Humana, Totowa, NJ
Print ISBN: 978-1-61779-339-4
Online ISBN: 978-1-61779-340-0
eBook Packages: Springer Protocols